

### Sedative Hypnotics

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

- Lexical No. 12. 7.113 information (patients) processes,		ann, mognoto, or not atta	med mill belief the fortion process.	
Member Name:	Preso	riber Name:		
HPP Member Number:	Fax:		Phone:	
Date of Birth:	Office	Contact:		
Member Primary Phone:	NPI:		PA PROMISe ID:	
Address:	Addre	ess:		
City, State ZIP:	City,	State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP	Spec	alty Pharmacy (if app	licable):	
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code: Diagr	nosis:			
HPP's maximum approval time		t may be less dependin	g on the drug.	
Please attach any pertinent medical history inclu	ding labe and i	oformation for this mo	mhor that may support approval	
	_		mber that may support approval.	
Please answer the following questions and sign.				
Q1. Is this a request for a sedative hypnotic that is a controlled substance?				
☐ Yes		No		
Q2. Is this a request for a sedative hypnotic that is a benzodiazepine?				
☐ Yes		No		
Q3. Is this the patient less than 21 years of age?				
☐ Yes		No		
Q4. Does the patient have a diagnosis of ONE of the following: A) seizure disorder, B) chemotherapy-induced nausea and vomiting, C) cerebral palsy, D) spastic disorder, E) dystonia, F) Catatonia?				
☐ Yes		No		
Q5. Is the patient receiving palliative care	?			
☐ Yes		No		
Q6. Is this a request for a renewal of authorization?				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



### Sedative Hypnotics

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:		
☐ Yes	□ No		
Q7. Does the patient have documentation of tolerability and a positive clinical response to the requested drug?			
☐ Yes	□ No		
Q8. Does the patient have a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder?			
☐ Yes	□ No		
Q9. Are the requested sedative hypnotic controlled substance and the buprenorphine agent prescribed by the same prescriber?			
☐ Yes	□ No		
Q10. Are the prescribers of the sedative hypnotic controlled substance and the buprenorphine agent aware of the other prescription(s)?			
☐ Yes	□ No		
Q11. Does the patient have an acute need for therapy with the sedative hypnotic controlled substance?			
☐ Yes	□ No		
Q12. Is this a request for a benzodiazepine when the patient has a recent claim for a benzodiazepine (i.e., potential therapeutic duplication)?			
☐ Yes	□ No		
Q13. Is the patient being titrated to, or tapered from, another benzodiazepine?			
☐ Yes	□ No		
Q14. Has the prescriber provided supporting peer reviewed literature or national treatment guidelines to corroborate concomitant use of the medications being requested?			
☐ Yes	□ No		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



### **Sedative Hypnotics**

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:		
Q15. Is this a request for a non-benzodiazepine sedative hypnotic when the patient has a recent claim for a non-benzodiazepine sedative hypnotic (i.e., potential therapeutic duplication)?			
☐ Yes	□ No		
Q16. Is the patient being titrated to, or tapered from, another non-benzodiazepine sedative hypnotic?			
☐ Yes	□ No		
Q17. Has the prescriber provided supporting peer reviewed literature or national treatment guidelines to corroborate concomitant use of the medications being requested?			
□Yes	□ No		
Q18. Does the patient have a record of 2 or more paid claims for any benzodiazepine in the past 30 days?			
□Yes	□ No		
Q19. Are the multiple benzodiazepine prescriptions consistent with medically accepted prescribing practices and standards of care, including support from peer-reviewed literature or national treatment guidelines?			
☐ Yes	□ No		
Q20. Are all of the prescriptions written by the same prescriber?			
☐ Yes	□ No		
Q21. Are all of the prescribers aware of the other prescription(s)?			
☐ Yes	□ No		
Q22. Does the patient have a diagnosis of non-24 hour sleep-wake disorder?			
☐ Yes	□ No		
Q23. Does the patient have a history of therapeutic failure of a 6-month trial of melatonin?			



### **Sedative Hypnotics**

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:		
☐ Yes	□ No		
Q24. Does the patient have a contraindication or intolerance to melatonin?			
□Yes	□ No		
Q25. Is this a request for a preferred sedative hypnotic drug?			
□Yes	□ No		
Q26. Is the requested drug being prescribed for the treatment of a diagnosis that is indicated in the FDA-approved package labeling OR a medically accepted diagnosis?			
☐ Yes	□ No		
Q27. Does the patient have a documented history of therapeutic failure, contraindication to, or intolerance of the preferred sedative hypnotic drugs that are approved or medically accepted for the patient's diagnosis or indication?			
☐ Yes	□ No		
Q28. Is this a request for a controlled-release sedative hypnotic?			
□Yes	□ No		
Q29. Does the patient have a history of therapeutic failure of the same regular-release sedative hypnotic drug?			
☐ Yes	□ No		
Q30. Additional Information:			
Prescriber Signature	Date		

v2025